ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV
At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.
You may also be interested in...
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.